1Gregoratos G, Cheitlin MD, Conill A, et al.: ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmic devices: A report of the ACC/AHA Task Force on practice guidelines, J Am Coil Cardiol 1998,31: 1175-1209.
2Lerman RD, Cannom DS: Indications for implantable cardioverter defibrillator therapy in year 2000, CEPR 2001, 5: 6-14.
3Wilber D J, Kall JG, Kopp DE: What can we expect from prophylactic implantable defibrillators? Am J Cardiol 1997, 80: 20F-27F.
4The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal sustained ventricular arrhythmias, N Engl J Med 1997, 337: 1576-1583,
5Connolly SJ, Gent M, Roberts RS, et al.: Canadian Implantable Defibrillator Study (CIDS): A randomized trial of the implantable cardioverter against amiodarone, Circulation 2000, 101: 1297-12302.
6Kuck KH, Cappato R, Siebels J, et al., for the CASH investigators. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest, Circulation 2000, 102: 748-754.
7Connolly SJ, Hallstrom AP, Cappato R, et al,, on behalf of the investigators of the AVID, CASH and CIDS studies. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials, Eur Heart J 2000, 21: 2071-1078.
8Domanski MJ, Saksena S, Epstein AE, et al.: Relative effectiveness of the implantable cardioverter defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias, J Am Coll Cardiol 1999, 34: 1090-1095.
9Sheldon R, Connolly S, Krahn A, et al.: Identification of patients most likely to benefit from implantable cardioverter defibrillator therapy, The Canadian implantable defibrillator study, Circulation 2000, 101: 1660-1664.
10Equity Research Bank of America Securities, April 30, 2001.
